Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally

San Diego, CA (PRWEB) January 14, 2014

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that they have entered into an international license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogens proprietary multipotent cell conditioned media (CCM).

This agreement is an amendment to the existing license between Histogen and Suneva Medical, through which Suneva has exclusively licensed the Regenica skincare line within the United States since February 2012. Under the terms of the international agreement, Suneva Medical is now the exclusive licensee for the distribution of Regenica through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East.

Not only has Suneva had sales success, but they have generated enthusiasm around the Regenica product line and our technology here in the US, said Gail K. Naughton, Ph.D., CEO and Chairman of the Board of Histogen. We are excited about expanding our skincare partnership internationally, and look forward to an exciting year for Regenica.

Regenica contains Histogens proprietary Multipotent Cell Conditioned Media, made up of soluble cell-signaing proteins and growth factors which support the bodys epidermal stem cells and renew skin throughout life. Through Histogens technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal and scarless healing.

We believe that Regenica truly is the next generation in growth factor technology, and we are extremely pleased that the products will now have a presence around the world, said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. Our relationship with Histogen in the US physician market has been a valuable asset to Suneva, and has laid the groundwork for international success.

About Histogen

Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen's process can be found in skincare products including ReGenica, which is distributed by Suneva Medical in partnership with Obagi Medical Products. For more information, please visit http://www.histogen.com.

About Suneva Medical, Inc.

Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets Artefill in the US, Korea, Singapore and Vietnam; Refissa and Regenica Skincare in the U.S.; and Bellafill in Canada. For more information, visit http://www.sunevamedical.com.

Read the rest here:
Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally